In a recent study of statin-treated patients with evidence of ASCVD and elevated Lp(a), we found that alirocumab significantly decreased plasma Lp(a) concentration chiefly by accelerating the FCR of Lp(a) particles (Watts et al., 2020). The gene discussed is LPA; the disease is atherosclerosis.